Abstract 100P
Background
Colon cancer (CC) is one of the most common malignancies in the world. In this study, we investigated the involvement of a mitosis related chromosome condensation protein NCAPG in tumor progression, and in the prognosis of human CC.
Methods
The patient cohort in this study consisted of 123 CC cases from 2009 to 2013, documenting pathologic and clinical factors, as well as clinical outcomes. Immunohistochemistry and immunoblotting were employed to examine the NCAPG expression in 123 pairs of normal and CC tissues and 7 colon cells. Based on the expression of NCAPG, one CC cell with high NCAPG level was chosen for knockdown of NCAPG expression. The effect of NCAPG knockdown on the growth, migration and invasion of NCAPG-manipulated CC cells was examined.
Results
NCAPG protein overexpression was observed in 88 patients and was significantly correlated with depth of invasion, distant metastasis, staging, and poor disease-free and overall survival. Multivariate Cox regression analysis showed that NCAPG overexpression is an indenpendent prognostic marker for CC. Furthermore, NCAPG expression was elevated in several CC cells. In vitro experiments indicated that NCAPG knockdown inhibited CC cell growth, migration and invasion.
Conclusions
This study suggests that overexpression of NCAPG can be a useful marker for predicting the outcome of CC patients and that NCAPG targeting can represent a potential modality for treating CC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chi Mei Medical Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract